top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Oct 10, 2024
Alpha Tau Treats First Patient with Recurrent Lung Cancer
first patient with recurrent lung cancer has been treated, in a clinical trial at Hadassah Medical Center in Jerusalem, Israel.
Sep 20, 2024
FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in this...
Aug 22, 2024
Alpha Tau to Participate in multiple upcoming investor conferences
JERUSALEM, August 2 2 , 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 14, 2024
Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- First patient treated in May for liver metastases from colorectal cancer - - Publication in June in Cancers journal of long-term...
Jun 25, 2024
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin,...
May 22, 2024
Alpha Tau to Present at the Jefferies Global Healthcare Conference
JERUSALEM, May 21, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 21, 2024
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - -...
May 13, 2024
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
JERUSALEM, May 13, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
May 6, 2024
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first...
May 1, 2024
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 1, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative...
bottom of page